Xilio Therapeutics (XLO) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

XLO · Stock Price

USD 7.81-2.13 (-21.43%)

Market Cap: $45.5M

Historical price data

Market Cap: $45.5MPipeline: 2 drugsFounded: 2016HQ: Waltham, United States

Sector Ranking#56 in Immunotherapy / Immuno-Oncology #131 in Oncology (General)

Overview

Xilio Therapeutics is developing a new class of tumor-activated immuno-oncology therapies designed to overcome the dose-limiting toxicities of systemic agents. Its core achievement is a clinically-validated masking technology platform that has generated two Phase 1 candidates and attracted strategic partnerships with major pharmaceutical companies. The company's strategy is to leverage this platform to unlock the full therapeutic potential of proven mechanisms like CTLA-4 inhibition and IL-2, confining their potent activity to the site of the tumor to improve the therapeutic index.

Oncology

Technology Platform

Proprietary Tumor-Activated Immuno-Oncology (TAIO™) platform that uses protease-cleavable masks to keep therapeutic biologics inactive in circulation until selectively activated by tumor-specific proteases within the tumor microenvironment.

Pipeline

2

2 drugs in pipeline

Drug	Indication	Stage	Watch
XTX202	Advanced Solid Tumor	Phase 1/2
XTX301	Advanced Solid Tumor	Phase 1/2

Funding History

1

Total raised:$71M

Series A$71MMRL Ventures FundJan 15, 2019

Opportunities

The core opportunity is to expand the use of potent but toxic immuno-oncology agents like CTLA-4 inhibitors and IL-2 by localizing their activity to tumors, potentially unlocking multi-billion dollar markets.

The modular TAIO™ platform also allows for expansion into new modalities and targets, creating a pipeline-in-a-product opportunity validated by strategic partnerships.

Risk Factors

The primary risks are clinical, as the company's value hinges on Phase 1 data demonstrating a superior therapeutic index for its lead candidates.

Platform validation risk, intense competition from other localized therapy approaches, and future capital needs present significant challenges.

Competitive Landscape

Xilio competes directly with other conditional activation platforms like CytomX's Probody® technology, as well as indirectly with developers of next-generation systemic agents and other localized delivery methods. Its partnerships and focused pipeline on high-value targets like CTLA-4 and IL-2 define its strategic niche.